Loading…
Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer
Non-small cell lung cancer (NSCLC) is the common type of lung cancer, which is the leading cause of cancer death throughout the world. Most patients were diagnosed too late for curative treatment. So, it is necessary to develop a minimal invasive method to identify NSCLC at an early stage. In recent...
Saved in:
Published in: | Tumor biology 2015-01, Vol.36 (1), p.7-19 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c471t-bb6abda0e3be1a22f02596e192f259d5616d33d73c2aa5feec9a08ffda26a4ac3 |
---|---|
cites | cdi_FETCH-LOGICAL-c471t-bb6abda0e3be1a22f02596e192f259d5616d33d73c2aa5feec9a08ffda26a4ac3 |
container_end_page | 19 |
container_issue | 1 |
container_start_page | 7 |
container_title | Tumor biology |
container_volume | 36 |
creator | Nie, Kun Jia, Yujie Zhang, Xuezhu |
description | Non-small cell lung cancer (NSCLC) is the common type of lung cancer, which is the leading cause of cancer death throughout the world. Most patients were diagnosed too late for curative treatment. So, it is necessary to develop a minimal invasive method to identify NSCLC at an early stage. In recent years, cell-free circulating tumor DNA (ctDNA) has attracted increasing attention as a potential tumor marker for its minimal invasive, convenient, and easily accepted properties. The amount of ctDNA in plasma or serum was significantly higher in NSCLC patients than that in healthy controls or patients with benign diseases. Furthermore, many studies have proved an association among tumor stage, tumor grade, lymph node involvement, the number of metastatic sites, tumor response, survival outcome, and the ctDNA levels. Many genetic changes, such as gene mutation, loss of heterozygosity, microsatellite instability, and gene methylation were also found in ctDNA in NSCLC patients. These findings demonstrated that the ctDNA could serve as a viable tool to monitor NSCLC and prompted us to find more sensitive and specific biomarkers for clinical practice, especially monitor these cases with at least one known gene abnormality. Here, we reviewed the evidence of ctDNA in NSCLC and consider possible future applications in patient management. |
doi_str_mv | 10.1007/s13277-014-2758-3 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1660439398</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1660439398</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-bb6abda0e3be1a22f02596e192f259d5616d33d73c2aa5feec9a08ffda26a4ac3</originalsourceid><addsrcrecordid>eNqNkUtLAzEYRYMotlZ_gBsJuHET--UxjyxLfULVja5DJpOUKfOoyczCf2-GVhFBcJWP5NybhIPQOYVrCpDNA-UsywhQQViW5IQfoCkVjBPgORzGGSgQwXI-QSchbABoImV6jCYs4QkDJqfoaWnrmjhvLTaVN0Ot-6pd435oOo9vnhe4avG21qHR82D90ODO4bZrSdyoa2xiGNdDDBjdGutP0ZHTdbBn-3WG3u5uX5cPZPVy_7hcrIgRGe1JUaS6KDVYXliqGXPAEplaKpmLQ5mkNC05LzNumNaJs9ZIDblzpWapFtrwGbra9W599z7Y0KumCuNjdGu7ISiapiC45DL_B5owIYRkMqKXv9BNN_g2fmSkgEuZZRApuqOM70Lw1qmtrxrtPxQFNWpROy0qalGjFsVj5mLfPBSNLb8TXx4iwHZAiEft2vofV__Z-glpEZaY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1650399770</pqid></control><display><type>article</type><title>Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer</title><source>Publicly Available Content Database</source><creator>Nie, Kun ; Jia, Yujie ; Zhang, Xuezhu</creator><creatorcontrib>Nie, Kun ; Jia, Yujie ; Zhang, Xuezhu</creatorcontrib><description>Non-small cell lung cancer (NSCLC) is the common type of lung cancer, which is the leading cause of cancer death throughout the world. Most patients were diagnosed too late for curative treatment. So, it is necessary to develop a minimal invasive method to identify NSCLC at an early stage. In recent years, cell-free circulating tumor DNA (ctDNA) has attracted increasing attention as a potential tumor marker for its minimal invasive, convenient, and easily accepted properties. The amount of ctDNA in plasma or serum was significantly higher in NSCLC patients than that in healthy controls or patients with benign diseases. Furthermore, many studies have proved an association among tumor stage, tumor grade, lymph node involvement, the number of metastatic sites, tumor response, survival outcome, and the ctDNA levels. Many genetic changes, such as gene mutation, loss of heterozygosity, microsatellite instability, and gene methylation were also found in ctDNA in NSCLC patients. These findings demonstrated that the ctDNA could serve as a viable tool to monitor NSCLC and prompted us to find more sensitive and specific biomarkers for clinical practice, especially monitor these cases with at least one known gene abnormality. Here, we reviewed the evidence of ctDNA in NSCLC and consider possible future applications in patient management.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-014-2758-3</identifier><identifier>PMID: 25352029</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Carcinoma, Non-Small-Cell Lung - blood ; Carcinoma, Non-Small-Cell Lung - genetics ; Deoxyribonucleic acid ; DNA ; DNA Methylation ; DNA, Neoplasm - blood ; DNA, Neoplasm - genetics ; Humans ; Loss of Heterozygosity ; Lung cancer ; Lung Neoplasms - blood ; Lung Neoplasms - genetics ; Microsatellite Instability ; Mutation ; Plasma ; Receptor, Epidermal Growth Factor - genetics ; Review ; Tumors</subject><ispartof>Tumor biology, 2015-01, Vol.36 (1), p.7-19</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2014</rights><rights>International Society of Oncology and BioMarkers (ISOBM) 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-bb6abda0e3be1a22f02596e192f259d5616d33d73c2aa5feec9a08ffda26a4ac3</citedby><cites>FETCH-LOGICAL-c471t-bb6abda0e3be1a22f02596e192f259d5616d33d73c2aa5feec9a08ffda26a4ac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1650399770?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,37013,44590</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25352029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nie, Kun</creatorcontrib><creatorcontrib>Jia, Yujie</creatorcontrib><creatorcontrib>Zhang, Xuezhu</creatorcontrib><title>Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer</title><title>Tumor biology</title><addtitle>Tumor Biol</addtitle><addtitle>Tumour Biol</addtitle><description>Non-small cell lung cancer (NSCLC) is the common type of lung cancer, which is the leading cause of cancer death throughout the world. Most patients were diagnosed too late for curative treatment. So, it is necessary to develop a minimal invasive method to identify NSCLC at an early stage. In recent years, cell-free circulating tumor DNA (ctDNA) has attracted increasing attention as a potential tumor marker for its minimal invasive, convenient, and easily accepted properties. The amount of ctDNA in plasma or serum was significantly higher in NSCLC patients than that in healthy controls or patients with benign diseases. Furthermore, many studies have proved an association among tumor stage, tumor grade, lymph node involvement, the number of metastatic sites, tumor response, survival outcome, and the ctDNA levels. Many genetic changes, such as gene mutation, loss of heterozygosity, microsatellite instability, and gene methylation were also found in ctDNA in NSCLC patients. These findings demonstrated that the ctDNA could serve as a viable tool to monitor NSCLC and prompted us to find more sensitive and specific biomarkers for clinical practice, especially monitor these cases with at least one known gene abnormality. Here, we reviewed the evidence of ctDNA in NSCLC and consider possible future applications in patient management.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Carcinoma, Non-Small-Cell Lung - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA Methylation</subject><subject>DNA, Neoplasm - blood</subject><subject>DNA, Neoplasm - genetics</subject><subject>Humans</subject><subject>Loss of Heterozygosity</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - blood</subject><subject>Lung Neoplasms - genetics</subject><subject>Microsatellite Instability</subject><subject>Mutation</subject><subject>Plasma</subject><subject>Receptor, Epidermal Growth Factor - genetics</subject><subject>Review</subject><subject>Tumors</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqNkUtLAzEYRYMotlZ_gBsJuHET--UxjyxLfULVja5DJpOUKfOoyczCf2-GVhFBcJWP5NybhIPQOYVrCpDNA-UsywhQQViW5IQfoCkVjBPgORzGGSgQwXI-QSchbABoImV6jCYs4QkDJqfoaWnrmjhvLTaVN0Ot-6pd435oOo9vnhe4avG21qHR82D90ODO4bZrSdyoa2xiGNdDDBjdGutP0ZHTdbBn-3WG3u5uX5cPZPVy_7hcrIgRGe1JUaS6KDVYXliqGXPAEplaKpmLQ5mkNC05LzNumNaJs9ZIDblzpWapFtrwGbra9W599z7Y0KumCuNjdGu7ISiapiC45DL_B5owIYRkMqKXv9BNN_g2fmSkgEuZZRApuqOM70Lw1qmtrxrtPxQFNWpROy0qalGjFsVj5mLfPBSNLb8TXx4iwHZAiEft2vofV__Z-glpEZaY</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Nie, Kun</creator><creator>Jia, Yujie</creator><creator>Zhang, Xuezhu</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7TM</scope></search><sort><creationdate>20150101</creationdate><title>Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer</title><author>Nie, Kun ; Jia, Yujie ; Zhang, Xuezhu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-bb6abda0e3be1a22f02596e192f259d5616d33d73c2aa5feec9a08ffda26a4ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Carcinoma, Non-Small-Cell Lung - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA Methylation</topic><topic>DNA, Neoplasm - blood</topic><topic>DNA, Neoplasm - genetics</topic><topic>Humans</topic><topic>Loss of Heterozygosity</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - blood</topic><topic>Lung Neoplasms - genetics</topic><topic>Microsatellite Instability</topic><topic>Mutation</topic><topic>Plasma</topic><topic>Receptor, Epidermal Growth Factor - genetics</topic><topic>Review</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nie, Kun</creatorcontrib><creatorcontrib>Jia, Yujie</creatorcontrib><creatorcontrib>Zhang, Xuezhu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Nucleic Acids Abstracts</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nie, Kun</au><au>Jia, Yujie</au><au>Zhang, Xuezhu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer</atitle><jtitle>Tumor biology</jtitle><stitle>Tumor Biol</stitle><addtitle>Tumour Biol</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>36</volume><issue>1</issue><spage>7</spage><epage>19</epage><pages>7-19</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>Non-small cell lung cancer (NSCLC) is the common type of lung cancer, which is the leading cause of cancer death throughout the world. Most patients were diagnosed too late for curative treatment. So, it is necessary to develop a minimal invasive method to identify NSCLC at an early stage. In recent years, cell-free circulating tumor DNA (ctDNA) has attracted increasing attention as a potential tumor marker for its minimal invasive, convenient, and easily accepted properties. The amount of ctDNA in plasma or serum was significantly higher in NSCLC patients than that in healthy controls or patients with benign diseases. Furthermore, many studies have proved an association among tumor stage, tumor grade, lymph node involvement, the number of metastatic sites, tumor response, survival outcome, and the ctDNA levels. Many genetic changes, such as gene mutation, loss of heterozygosity, microsatellite instability, and gene methylation were also found in ctDNA in NSCLC patients. These findings demonstrated that the ctDNA could serve as a viable tool to monitor NSCLC and prompted us to find more sensitive and specific biomarkers for clinical practice, especially monitor these cases with at least one known gene abnormality. Here, we reviewed the evidence of ctDNA in NSCLC and consider possible future applications in patient management.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>25352029</pmid><doi>10.1007/s13277-014-2758-3</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1010-4283 |
ispartof | Tumor biology, 2015-01, Vol.36 (1), p.7-19 |
issn | 1010-4283 1423-0380 |
language | eng |
recordid | cdi_proquest_miscellaneous_1660439398 |
source | Publicly Available Content Database |
subjects | Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - genetics Deoxyribonucleic acid DNA DNA Methylation DNA, Neoplasm - blood DNA, Neoplasm - genetics Humans Loss of Heterozygosity Lung cancer Lung Neoplasms - blood Lung Neoplasms - genetics Microsatellite Instability Mutation Plasma Receptor, Epidermal Growth Factor - genetics Review Tumors |
title | Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A01%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cell-free%20circulating%20tumor%20DNA%20in%20plasma/serum%20of%20non-small%20cell%20lung%20cancer&rft.jtitle=Tumor%20biology&rft.au=Nie,%20Kun&rft.date=2015-01-01&rft.volume=36&rft.issue=1&rft.spage=7&rft.epage=19&rft.pages=7-19&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-014-2758-3&rft_dat=%3Cproquest_cross%3E1660439398%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c471t-bb6abda0e3be1a22f02596e192f259d5616d33d73c2aa5feec9a08ffda26a4ac3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1650399770&rft_id=info:pmid/25352029&rfr_iscdi=true |